vs
Arcellx, Inc.（ACLX）与BioNTech SE（BNTX）财务数据对比。点击上方公司名可切换其他公司
BioNTech SE的季度营收约是Arcellx, Inc.的918.3倍（$1.5B vs $1.7M）。BioNTech SE净利率更高（-1.9% vs -3513.4%，领先3511.5%）
Arcellx, Inc.是一家处于临床阶段的生物技术企业，专注开发用于治疗血液恶性肿瘤、实体瘤等难治性癌症的CAR-T细胞疗法，其核心管线针对肿瘤领域未被满足的医疗需求，服务全球患者群体。
BioNTech SE是总部位于德国美因茨的跨国生物技术企业，专注于免疫疗法及疫苗研发工作，核心研究方向覆盖肿瘤、传染性疾病等医疗领域，相关技术处于全球生物医药行业领先水平。
ACLX vs BNTX — 直观对比
营收规模更大
BNTX
是对方的918.3倍
$1.7M
净利率更高
BNTX
高出3511.5%
-3513.4%
损益表 — Q4 2025 vs Q3 2025
| 指标 | | |
|---|---|---|
| 营收 | $1.7M | $1.5B |
| 净利润 | $-58.1M | $-28.7M |
| 毛利率 | — | — |
| 营业利润率 | -3850.2% | -3.1% |
| 净利率 | -3513.4% | -1.9% |
| 营收同比 | -89.2% | — |
| 净利润同比 | -23.4% | — |
| 每股收益（稀释后） | $-1.01 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ACLXBNTX
| Q4 25 | $1.7M | — | ||
| Q3 25 | $4.9M | $1.5B | ||
| Q2 25 | $7.6M | $260.8M | ||
| Q1 25 | $8.1M | $182.8M | ||
| Q4 24 | $15.3M | — | ||
| Q3 24 | $26.0M | $1.2B | ||
| Q2 24 | $27.4M | $128.7M | ||
| Q1 24 | $39.3M | $187.6M |
净利润ACLXBNTX
| Q4 25 | $-58.1M | — | ||
| Q3 25 | $-55.8M | $-28.7M | ||
| Q2 25 | $-52.8M | $-386.6M | ||
| Q1 25 | $-62.3M | $-415.8M | ||
| Q4 24 | $-47.1M | — | ||
| Q3 24 | $-25.9M | $198.1M | ||
| Q2 24 | $-27.2M | — | ||
| Q1 24 | $-7.2M | — |
营业利润率ACLXBNTX
| Q4 25 | -3850.2% | — | ||
| Q3 25 | -1248.3% | -3.1% | ||
| Q2 25 | -777.4% | -192.1% | ||
| Q1 25 | -847.6% | -292.2% | ||
| Q4 24 | -348.2% | — | ||
| Q3 24 | -129.1% | 0.8% | ||
| Q2 24 | -127.8% | -750.7% | ||
| Q1 24 | -40.3% | -270.4% |
净利率ACLXBNTX
| Q4 25 | -3513.4% | — | ||
| Q3 25 | -1127.1% | -1.9% | ||
| Q2 25 | -698.6% | -148.2% | ||
| Q1 25 | -766.0% | -227.5% | ||
| Q4 24 | -308.4% | — | ||
| Q3 24 | -99.4% | 15.9% | ||
| Q2 24 | -99.3% | — | ||
| Q1 24 | -18.3% | — |
每股收益（稀释后）ACLXBNTX
| Q4 25 | $-1.01 | — | ||
| Q3 25 | $-0.99 | — | ||
| Q2 25 | $-0.94 | — | ||
| Q1 25 | $-1.13 | — | ||
| Q4 24 | $-0.87 | — | ||
| Q3 24 | $-0.48 | — | ||
| Q2 24 | $-0.51 | — | ||
| Q1 24 | $-0.14 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $450.3M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $402.4M | — |
| 总资产 | $604.0M | — |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ACLXBNTX
| Q4 25 | $450.3M | — | ||
| Q3 25 | $461.4M | — | ||
| Q2 25 | $453.1M | — | ||
| Q1 25 | $543.3M | — | ||
| Q4 24 | $587.4M | — | ||
| Q3 24 | $574.3M | — | ||
| Q2 24 | $516.7M | — | ||
| Q1 24 | $573.9M | — |
股东权益ACLXBNTX
| Q4 25 | $402.4M | — | ||
| Q3 25 | $440.8M | — | ||
| Q2 25 | $392.2M | — | ||
| Q1 25 | $416.9M | — | ||
| Q4 24 | $454.8M | — | ||
| Q3 24 | $483.0M | — | ||
| Q2 24 | $487.2M | — | ||
| Q1 24 | $496.6M | — |
总资产ACLXBNTX
| Q4 25 | $604.0M | — | ||
| Q3 25 | $655.9M | — | ||
| Q2 25 | $619.1M | — | ||
| Q1 25 | $648.1M | — | ||
| Q4 24 | $711.3M | — | ||
| Q3 24 | $764.9M | — | ||
| Q2 24 | $734.3M | — | ||
| Q1 24 | $779.7M | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-58.2M | — |
| 自由现金流经营现金流 - 资本支出 | $-58.9M | — |
| 自由现金流率自由现金流/营收 | -3563.4% | — |
| 资本支出强度资本支出/营收 | 46.2% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-212.6M | — |
8季度趋势，按日历期对齐
经营现金流ACLXBNTX
| Q4 25 | $-58.2M | — | ||
| Q3 25 | $-49.2M | — | ||
| Q2 25 | $-39.7M | — | ||
| Q1 25 | $-63.1M | — | ||
| Q4 24 | $-46.0M | — | ||
| Q3 24 | $30.7M | — | ||
| Q2 24 | $-36.2M | — | ||
| Q1 24 | $-31.9M | — |
自由现金流ACLXBNTX
| Q4 25 | $-58.9M | — | ||
| Q3 25 | $-49.5M | — | ||
| Q2 25 | $-40.2M | — | ||
| Q1 25 | $-63.9M | — | ||
| Q4 24 | $-47.5M | — | ||
| Q3 24 | $28.4M | — | ||
| Q2 24 | $-39.5M | — | ||
| Q1 24 | $-38.3M | — |
自由现金流率ACLXBNTX
| Q4 25 | -3563.4% | — | ||
| Q3 25 | -1000.3% | — | ||
| Q2 25 | -532.4% | — | ||
| Q1 25 | -786.4% | — | ||
| Q4 24 | -311.3% | — | ||
| Q3 24 | 109.2% | — | ||
| Q2 24 | -144.1% | — | ||
| Q1 24 | -97.7% | — |
资本支出强度ACLXBNTX
| Q4 25 | 46.2% | — | ||
| Q3 25 | 6.0% | — | ||
| Q2 25 | 6.4% | — | ||
| Q1 25 | 9.6% | — | ||
| Q4 24 | 9.8% | — | ||
| Q3 24 | 8.8% | — | ||
| Q2 24 | 11.7% | — | ||
| Q1 24 | 16.4% | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
